For all media queries please contact our Communications Advisor.
Recent statements in the media misrepresent the Medicines New Zealand position on the Trans-Pacific Partnership and are not helpful to New Zealanders waiting for better access to innovative medicines.
"We are outraged that the Minister of Health has today confirmed $30 million of PHARMAC’s budget was not reinvested in medicines in 2015. PHARMAC’s gross underfunding has left New Zealanders missing out on innovative medicines"
New Zealanders are waiting for over 35 cost-effective medicines recommended by PHARMAC's technical advisory committee.
Medicines New Zealand believes that strong intellectual property protections are necessary for the discovery and development of new treatments and therapies for New Zealand patients, including innovative biologic medicines.
Medicines New Zealand believes signing of the TPP has potential to boost the New Zealand economy by between $2-4 billion per year, open up new markets for our exporters, and allow New Zealanders improved access to innovative and beneficial goods including medicines and vaccines.